Explorez tous les épisodes du podcast The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
| Titre | Date | Durée | |
|---|---|---|---|
| Daily Roundup | J&J to Buy Ollin for $2.2B Upfront & Roche’s Wilserdly Combo Approved for Breast Cancer | 17 Nov 2026 | 00:11:40 | |
In this delayed Monday closeout, Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, and Blackstone agreed to fund Phase 3 work on OLN324 in wet AMD and diabetic macular edema if the acquisition closes. The FDA approved Roche's Wilserdly (giredestrant) with everolimus for ESR1-mutated advanced breast cancer after endocrine therapy. In the daily roundup: CG Oncology's cretostimogene bladder cancer data, Servier's Ojemda (tovorafenib) follow-up in pediatric low-grade glioma, Lilly's Calytrix Bio deal, AstraZeneca's Klygefa (gefurulimab) approval in myasthenia gravis, Novo Nordisk's semaglutide data in children, and AriBio's split AR1001 Alzheimer's result. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Week in Review | Summit's FDA Setback, Novo's Obesity Data & Pfizer's Blackstone Deal | 16 Nov 2026 | 00:46:13 | |
Delayed Sunday, November 15 edition. Summit says the FDA issued a complete response letter for ivonescimab plus chemotherapy in previously treated EGFR-mutated lung cancer. Novo Nordisk detailed two lower doses of CagriSema in obesity, and Pfizer arranged development funding of up to $1.5 billion from Blackstone-managed funds for its investigational monthly GLP-1 berobenatide. We also cover FDA approvals for Gazyva (obinutuzumab) in adults with primary membranous nephropathy at risk of progression, and Imfinzi (durvalumab) with Padcev (enfortumab vedotin) in bladder cancer, new CHMP opinions, three hereditary angioedema updates, and the week ahead at ObesityWeek and CTAD. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Imfinzi + Padcev Add Bladder Surgery Option & Rezolute: 12 of 16 Stop IV Glucose in Preliminary Data | 14 Nov 2026 | 00:13:56 | |
The FDA approved Imfinzi (durvalumab) plus Padcev (enfortumab vedotin-ejfv) before bladder removal, then Imfinzi alone afterward, for adults with muscle-invasive bladder cancer who cannot receive or decline cisplatin-based chemotherapy. In Rezolute’s preliminary single-arm Phase 3 upLIFT readout of ersodetug for tumor-related hyperinsulinism, 13 of 16 patients at least halved their IV glucose infusion rate, including 12 who stopped IV glucose. The November 12–13 roundup covers split European recommendations on Baxfendy (baxdrostat) and Meplyffa (arimoclomol), plus Intellia’s hereditary angioedema data. Windward Bio priced its IPO alongside a planned Sanofi placement, and Bristol Myers Squibb is unifying R&D. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | enGene Plans Bladder Cancer Filing & Mirum’s Second Hepatitis D Phase 3 Win | 13 Nov 2026 | 00:08:41 | |
enGene plans to start its FDA filing for detalimogene voraplasmid in bladder cancer by year-end after longer follow-up in a single-arm trial. Mirum’s brelovitug met the primary endpoint in a second Phase 3 hepatitis D trial, adding evidence for its planned US filing. Also covered: BioNTech’s $205 million deal for Scholar Rock’s priority review voucher, PepGen’s PGN-EDODM1 splicing data in myotonic dystrophy type 1, Oyster Therapeutics’ financing for its tau program, and Summit’s November 14 FDA goal date for ivonescimab plus chemotherapy in EGFR-mutated lung cancer. This is the delayed November 11, 2026 edition, released November 12. Alex Mercer and Maya Patel host. Sources enGene — LEGEND and filing plan https://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspx Mirum — AZURE-4 and filing plan https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-AZURE-4-Phase-3-Study-and-Highlights-Long-Term-Brelovitug-Data-Presented-at-AASLD/default.aspx BioNTech — priority review voucher agreement https://www.biontech.com/us/en/home/mediaroom/news/statements/2026/11/BioNTech-to-Acquire-US-FDA-Priority-Review-Voucher.html PepGen — FREEDOM2-DM1 and partial clinical hold https://investors.pepgen.com/node/9531/html 4BIO Capital — Oyster Therapeutics financing https://www.4biocapital.com/single-post/oyster-series-a Summit Therapeutics — HARMONi and FDA goal date https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/ | |||
| Daily Roundup | Bayer's Stroke Approval Puts Bleeding Risk in Focus & Beam Nears Sickle Cell Filing | 12 Nov 2026 | 00:12:31 | |
Delayed release of the November 10, 2026 edition. News reflects the November 10 research cutoff. Bayer's Sunharbo (asundexian) wins FDA approval for stroke prevention, with bleeding risks shaping patient selection. Beam's risto-cel meets its pivotal sickle cell goal, but a year-end filing could precede detailed public results. Lilly's Foundayo (orforglipron) sleep apnea data, Boehringer and Zealand's survodutide safety result, and the FDA's GLP-1 vision-warning action put benefit and tolerability in focus. Also: Novocure's Optune Mya setback in lung-cancer brain metastases, EMD Serono's pimicotinib approval for tenosynovial giant cell tumor, Compass's COMP360 depression filing, and argenx's deal for Unnatural Products. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Week in Review | Vir's Hepatitis Delta Result & CVS Split Plan: Full Recap | 10 Nov 2026 | 00:48:17 | |
In this full November 2–8 recap, 44% of treated patients in Vir's hepatitis delta trial met the Phase 3 primary endpoint, with an important difference in when the comparison groups were measured. CVS plans to separate its retail pharmacies and MinuteClinic from Aetna and Caremark, subject to conditions. Alex and Maya also examine HOVON 150 in IDH1-mutated leukemia, FDA's Zolgensma safety investigation, cardiovascular data and the week's deals and manufacturing news — and what the evidence does and does not show. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | ANI's Recommended Egetis Offer & BHB-1893 Heart Study: Most End on Starting Dose | 07 Nov 2026 | 00:09:54 | |
ANI Pharmaceuticals made a recommended cash offer of about 5.3 billion kronor for Egetis Therapeutics, maker of Emcitate (tiratricol); the acceptance period is expected to open around November 20. Braveheart and Hengrui reported 52-week open-label data, with no comparison group, for oral BHB-1893 in adults with symptomatic obstructive HCM: 33 of 42 had a provoked gradient below 30 mmHg and 24 ended on the starting dose. Also: Amgen's real-world Repatha (evolocumab) vs. ezetimibe study; Lilly and Hims & Hers on Zepbound (tirzepatide) and Foundayo (orforglipron) self-pay access; Agios R&D role cuts; Moderna's norovirus cohort decision; and its Q3 revenue and raised outlook. This is the original Friday, November 6 edition, released late. | |||
| Daily Roundup | Rybrevant Faspro Gets Accelerated FDA Nod in Head and Neck Cancer & Tibsovo Lifts EFS in Fit AML | 07 Nov 2026 | 00:14:33 | |
J&J's Rybrevant Faspro (amivantamab) won accelerated FDA approval in later-line head and neck cancer on a 42% single-arm response rate. A HOVON trial adding Tibsovo (ivosidenib) to intensive chemotherapy in IDH1-mutated AML showed a large interim event-free survival gain, though overall survival is not reported. The daily roundup covers ASH detail on Genmab and AbbVie's epcoritamab plus lenalidomide in lymphoma and Pfizer's Elrexfio (elranatamab) in myeloma, Boehringer Ingelheim's staged six-program deal with SBP Group, and the FDA's Nov 6 Zolgensma cancer-risk alert in spinal muscular atrophy. Akebia's VOCAL trial of Vafseo (vadadustat) in dialysis anemia closes this original November 5 edition, released on a delayed schedule. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | CVS plans to split pharmacies from Aetna and Caremark & AbbVie licenses Nxera's IBD drug | 07 Nov 2026 | 00:09:03 | |
CVS Health plans to split into two public companies, separating about 9,000 pharmacies from Aetna and Caremark, targeting the first half of 2028. This delayed November 4 edition also covers AbbVie's IBD license for Nxera's gut-targeted NXE0033744: $100 million upfront, up to $1.37 billion in milestones, and no IBD efficacy results in the announcement. In the roundup: FDA priority review for BeOne's Brukinsa (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, and Pfizer's November 3 snapshot of discontinued obesity, PAH and KRAS programs. Plus Novo Nordisk's diverging Q3 operating profit measures and FDA Breakthrough Therapy designation for Idorsia's daridorexant in pediatric insomnia. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Fresenius gains access to up to 37 biosimilar candidates via WuXi & Supernus-Indivior merger closes | 07 Nov 2026 | 00:09:33 | |
Fresenius gains exclusive access to up to 37 biosimilar candidates through WuXi Biologics, with initial development expected on biosimilars of polatuzumab vedotin and teprotumumab. Supernus and Indivior complete their merger, leaving former Indivior holders with about 56.5% of Supernus, Inc., while a separate $1 billion dividend is partly funded by a loan to the combined company. In neurology, Bright Minds reports an FDA partial hold on a planned BMB-101 Phase 2 study, Tiziana reports INFORM-MS data for foralumab, and Novartis ends a BrainTransporter deal with BioArctic. This delayed November 2 edition cites Samsung Biologics' later November 5 definitive figures: 97.66% of PolyPeptide's issued share capital and voting rights tendered. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Servier Drug Misses Becker Trial & Karyopharm Files Chapter 11 | 05 Nov 2026 | 00:11:37 | |
Servier's sevasemten missed its pivotal Becker muscular dystrophy trial, while Karyopharm filed Chapter 11 and proposed an Ayrmid deal around XPOVIO. This delayed November 3, 2026 edition reports dated developments: 'today' means November 3 and 'Monday' November 2. Also covered: uniQure's AMT-130 application, Teva's TOPAS-MSA stop, FDA potency guidance, InventisBio's psoriasis results, Recursion's REC-4881 data, Dr. Reddy's tentative lenacapavir approval reported by CHAI, Rhythm's LG Chem amendment and Pfizer's forecast. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Week in Review | Estrogen Patch Boxed Warnings Revised, Novartis Writes Down Del-Desiran & Acumen Ends Sabirnetug | 03 Nov 2026 | 00:37:34 | |
November 1, 2026 edition — delayed release. This recap covers October 26–30; its dated week-ahead items reflect preparation-time previews, not subsequently reported results. The FDA removed the cardiovascular disease, breast cancer and probable dementia risk statements from the boxed warnings on the Minivelle, Vivelle and Vivelle-Dot estradiol patches; Minivelle keeps its endometrial cancer box, and all three remain prescription products. Novartis took a $1.94 billion partial, noncash impairment on del-desiran after September's HARBOR miss, and Acumen ended sabirnetug after its Phase 2 Alzheimer's trial reduced plaque but missed on cognition and function. We also cover the FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide), Lilly's retatrutide head-to-head against Ozempic (semaglutide), Genmab's petosemtamab survival result, Ilumya's psoriatic arthritis approval and Agios's new mitapivat decision date. Then the dated week ahead: Pfizer, Novo Nordisk, Recursion, SITC and AHA. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| ESMO 2026 Debrief: A 12-Week Checkpoint Dosing Trial Stopped Early & Ivonescimab Beats Imfinzi on Survival in Biliary Cancer | 02 Nov 2026 | 00:20:44 | |
The Pharma Closeout's ESMO 2026 Debrief brings you the readouts from the European Society for Medical Oncology congress in Madrid that matter, what they change, and what to watch next, with one thread running through them: how much checkpoint therapy is enough. MOIO, a French trial that spaced checkpoint-inhibitor doses to every 12 weeks in patients already responding, was stopped early on its monitoring committee's recommendation. Around bladder surgery, Merck's KEYNOTE-866 and Bristol Myers Squibb's ENERGIZE both missed event-free survival in cisplatin-eligible patients, while VOLGA won in patients ineligible for or declining cisplatin, and final PEARLS survival for adjuvant Keytruda in lung cancer missed significance. Then mismatch repair-deficient tumors, with a correction on GSK's AZUR-1 numbers; Akeso and Summit's ivonescimab beating AstraZeneca's Imfinzi on survival in biliary tract cancer at an interim analysis; Tagrisso plus Orpathys in two lines of lung cancer; Amgen's Imdelltra and a rival DLL3 drug in small-cell lung cancer; six-year NATALEE survival for Novartis's Kisqali; androgen-receptor drugs moving earlier in prostate cancer; and cancer vaccines, led by Merck and Moderna's intismeran. Plus what to watch: INTerpath-001's full results, slated for The New England Journal of Medicine on November 11, and the November 14 FDA goal date for ivonescimab in EGFR-mutated lung cancer. 0:00 Cold open and introduction 1:03 Story of the Congress: how much checkpoint is enough (MOIO, KEYNOTE-866, ENERGIZE, VOLGA, PEARLS) 5:45 Mismatch repair-deficient tumors: KEYNOTE-C93, TroFuse-005, the AZUR-1 correction and CheckMate 8HW 9:19 Biliary tract cancer: ivonescimab beats Imfinzi in HARMONi-GI1 10:43 Lung cancer: SAFFRON, SANOVO, sigvotatug vedotin and PERSEE 13:18 Small-cell lung cancer: DeLLphi-305, ASTRIDE and IDE849 14:37 Breast cancer: NATALEE at six years and postMONARCH 15:53 Prostate cancer: PROTEUS, DASL-HiCaP and J&J's RIPTAC 17:50 Cancer vaccines: intismeran, ELI-002 7P and DOVACC 19:08 What to watch: INTerpath-001 in NEJM and the ivonescimab FDA decision Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Acumen Ends Alzheimer's Antibody After Phase 2 Miss & Inovio's Voceryq Wins Accelerated Approval | 01 Nov 2026 | 00:12:05 | |
October 30 edition — delayed release on November 1. References to today and Friday in the audio refer to October 30. Acumen ends sabirnetug after a Phase 2 Alzheimer's trial lowered amyloid but missed on cognition and function, and Inovio's Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) won accelerated approval for adult recurrent respiratory papillomatosis, with benefit yet to be verified. Sun Pharma's Ilumya (tildrakizumab-asmn) is approved for active psoriatic arthritis, Agios' mitapivat sickle cell action date moved to February 1, 2027, and NRx says FDA approved its generic preservative-free ketamine. Dren Bio raised $350 million for dibotatug, and Setara $90 million for STAR-0871 in CMT2C. Regeneron's Eylea (aflibercept) and Sanofi's Dupixent (dupilumab) quarters and Nxera's operating-profit swing close it out. | |||
| Daily Roundup | Iovance Lung Data Points to a Subgroup & Ono Plans New Pain Studies After 3 Misses | 30 Oct 2026 | 00:14:41 | |
October 29, 2026 edition, released October 30. The audio reflects the October 29 roundup; the INO-3107 watch refers to an October 30 FDA target date, not an announced decision. Iovance's lifileucel produced responses in 17 of 69 previously treated non-squamous lung cancer patients who received at least 10 billion viable cells. A new cohort, POSITILITY, will select patients up front using a subgroup profile found in a retrospective analysis. Ono's ONO-1110 missed primary endpoints in three Phase 2 pain studies; Ono is planning further pain studies based on prespecified subgroup and post hoc signals, and plans no further studies in depression or social anxiety. The daily roundup covers BMS ending Prothena's PRX019 license, Rafael's remibetadex NDA in Niemann-Pick type C after a Phase 3 primary-endpoint miss, a BioMarin Fabry license, Alnylam's TRITON-CM expansion, Lilly and Merck third quarters, and a Labor Department PBM disclosure rule. | |||
| Daily Roundup | Genmab's Cancer Survival Gain & Lilly's Retatrutide Dose Trade-Off | 29 Oct 2026 | 00:10:56 | |
This is the October 28 edition of The Pharma Closeout, released October 29. Genmab's investigational petosemtamab combination improves survival against pembrolizumab alone in a first-line head-and-neck cancer trial, while Lilly's retatrutide raises a dose-choice question after greater weight loss and more adverse-event discontinuations than Ozempic (semaglutide) 2 mg in type 2 diabetes. Geron stops imetelstat's myelofibrosis trial; AbbVie files etentamig for multiple myeloma using previously reported CERVINO results; and Replimune reports early launch activity for TUDRIQEV (vusolimogene oderparepvec-wtpg) in melanoma. FDA's draft individualized gene-editing framework, CMS's planned gene-therapy access expansion and HHS's proposed conditional peptide-compounding policy remain distinct developments. GSK's sales mix shifts toward specialty medicines, and FDA staff questions set up the October 30 advisory committee on Sydnexis's atropine for pediatric myopia. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com. | |||
| Daily Roundup | Artiva Ends AlloNK, Cuts 94% of Staff & Ferring Agrees to Buy Gameto | 28 Oct 2026 | 00:10:10 | |
Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up to $1.3825 billion subject to milestones, before Fertilo's pivotal fertility trial reports. Pfizer's ELREXFIO (elranatamab) meets a Phase 3 myeloma goal with higher rates of severe infections; AstraZeneca and Daiichi Sankyo gain EU approval for Enhertu (trastuzumab deruxtecan) in postoperative HER2-positive early breast cancer; Novartis discontinues remibrutinib in generalized myasthenia gravis for futility. Also: Teva closes its BioXcel asset deal for IGALMI (dexmedetomidine) and the pending at-home BXCL501 program; Vanda's NEREUS (tradipitant) reduces vomiting in a single-dose semaglutide challenge; and Kiniksa raises its ARCALYST (rilonacept) sales forecast. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com. | |||
| Daily Roundup | BioNTech/DualityBio Breast ADC Gain Called Modest & Merck's sac-TMT Survival Edge Under FDA Review | 27 Oct 2026 | 00:09:12 | |
October 26, 2026 edition, released October 27. Recorded October 26: references to today mean October 26, and tomorrow means October 27. BioNTech and DualityBio's breast cancer ADC beat chemo in Phase 3, yet the companies call the gain modest. Merck and Kelun's sac-TMT showed interim median overall survival of 19.0 vs 12.1 months in endometrial cancer after platinum and immunotherapy and is under FDA priority review. Also: Keytruda (pembrolizumab) alone in first-line dMMR endometrial cancer; FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) for adults with metastatic, androgen pathway modulation-naive or -sensitive prostate cancer with HRR mutations detected by an FDA-authorized test; BMS/SystImmune's iza-bren in EGFR-mutated lung cancer; GSK/Hansoh's ris-rez in osteosarcoma; and Corxel US/Amanat's proposed deal that would help fund oral GLP-1 CX11. Sources: | |||
| Week in Review | Amgen's Survival Gain, Roche's KRAS Challenge & Gilead's IBD Deal | 26 Oct 2026 | 00:29:58 | |
Sunday, October 25 edition, released Monday, October 26 with the SANOVO update. Amgen's Imdelltra plus AstraZeneca's Imfinzi extended median survival to 21.1 months from 12.7 in extensive-stage small-cell lung cancer maintenance, while Roche's divarasib beat pooled KRAS G12C comparators. AstraZeneca's Sone-Ve delivered a gastric-cancer survival win beside a missed progression endpoint; SANOVO then showed Tagrisso plus Orpathys improved progression-free survival in untreated, biomarker-selected patients in China. Gilead's $1.275 billion PepStar IL-23 deal and AbbVie's Skyrizi Crohn's approval lead gastroenterology, with hematology, immunology, diagnostics and biotech investment rules rounding out the full Week in Review. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com. | |||
| Daily Roundup | Remibrutinib Cuts MS Relapses & Iza-bren Improves Breast Cancer PFS | 25 Oct 2026 | 00:14:08 | |
Delayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23. Novartis's investigational remibrutinib cut MS relapse rates 35.2% and 31.2% versus teriflunomide; Biokin's Bristol Myers Squibb/SystImmune-partnered iza-bren improved breast cancer PFS. Jazz/BeOne's Ziihera (zanidatamab), licensed from Zymeworks, has mature gastroesophageal survival data, while Tango reports pancreatic cancer responses with vopimetostat and Revolution Medicines' daraxonrasib. Johnson & Johnson's Tecvayli (teclistamab) moves earlier in European myeloma treatment, as we examine BMS's zola-cel safety in MS and Alnylam's brezosiran target engagement in Huntington's. Plus Bolt's Prana acquisition and Treasury's proposed biotech investment rules. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| UEG Week 2026 Debrief: Takeda's Treat-to-Target Test & Duvakitug's 44-Week TL1A Read | 24 Oct 2026 | 00:18:40 | |
The Pharma Closeout's UEG Week 2026 Debrief covers the readouts from United European Gastroenterology Week in Barcelona that matter for drug, device and payer strategy. Takeda's VERDICT, the first randomized treat-to-target strategy trial in ulcerative colitis, and the new STRIDE-III guidance sharpen what IBD treatment should aim at, and what that means for how therapies win switches. Then the orals (Abivax's obefazimod ahead of its NDA, Gilead's emvistegrast dose curve, J&J's icotrokinra), the TL1A race with Teva and Sanofi's first 44-week duvakitug data, the incumbents' franchise defense from AbbVie and J&J, Tremfya at week 48 in Crohn's with fistulas, and a gastroparesis drug heading to Phase 3. Plus what to watch: AbbVie's October 30 results, AASLD from November 5 and the November 27 PBC decision. 0:00 Cold open and introduction 0:50 Story of the Congress: the target, not the molecule (Takeda's VERDICT, STRIDE-III, PROFILE) 5:06 The orals: obefazimod, emvistegrast, icotrokinra and OD-001 8:38 The TL1A race: Teva and Sanofi's duvakitug 10:01 Franchise defense: AbbVie, J&J, Spyre and the biosimilar squeeze 13:26 The IL-23 incumbents: Tremfya in fistulizing Crohn's, Skyrizi's subcutaneous induction 15:26 Beyond IBD: gastroparesis, EoE and the liver 17:27 What to watch: AbbVie's results, AASLD and the PBC decision Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Merck-Moderna mRNA Cuts Melanoma Recurrence or Death & AbbVie HS Drug Hits Phase 3 Goal | 23 Oct 2026 | 00:11:11 | |
October 22, 2026 edition, released October 23. Reporting reflects the October 22 research cutoff. Merck and Moderna's investigational intismeran autogene, added to Keytruda (pembrolizumab) after surgery for high-risk cutaneous melanoma, posted a 0.58 hazard ratio for recurrence or death versus placebo plus Keytruda; overall survival is immature. AbbVie's investigational lutikizumab beat placebo in a Phase 3 hidradenitis suppurativa trial, 31.4% versus 23.4% on HiSCR75. The daily roundup covers BioNTech's planned pairing of pumitamig with Gilead's Trodelvy (sacituzumab govitecan), Menarini subsidiary Stemline's GIM-621 license from Georgiamune, Cencora's American Oncology Network deal and Roche's removal of RG6540 from its Phase 1 pipeline. It also covers Krystal Biotech's Vyjuvek (beremagene geperpavec) storage update, Biohaven's statement, reported by Dow Jones, that FDA accepted its Vyglxia resubmission, and QIAGEN's agreed EQT-led acquisition. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Brepocitinib Holds Uveitis Control Off Steroids; Oral Olorofim Shows Far Fewer Kidney Events | 22 Oct 2026 | 00:12:32 | |
October 21, 2026 edition, released October 22. Relative dates in the audio refer to October 21. Roivant's Priovant reports two positive Phase 3 trials of oral brepocitinib in non-infectious uveitis, run through a mandatory steroid taper. F2G and Shionogi add kidney, liver and hospital-stay detail from olorofim's OASIS trial, where survival was noninferior rather than better. Also in the daily roundup: Alcon completes its Neurotech acquisition, the European Commission approves perioperative Keytruda plus Padcev regardless of cisplatin eligibility, Summit and ECOG-ACRIN set up a trial of ivonescimab in biliary tract cancer, Roche discloses fenebrutinib lesion imaging ahead of its MSToronto presentation, TG releases data on a single-infusion Briumvi start, OpenAI acquires Orchestra Bio, and FDA's warning letter to Baxter becomes public. Sources: | |||
| Daily Roundup | GSK's Hibsago Offers a Path Off Hepatitis B Treatment & Tezspire Details EoE Data | 21 Oct 2026 | 00:14:12 | |
FDA approved GSK's Hibsago (bepirovirsen) for selected adults with chronic hepatitis B without cirrhosis, opening a possible path off long-term treatment after a staged treatment and testing process. We examine who qualifies, the B-Well results and the boxed safety warnings. Amgen and AstraZeneca's detailed Phase 3 CROSSING results show Tezspire's biopsy remission and swallowing outcomes in eosinophilic esophagitis, where Dupixent is already established. The daily roundup covers Rapport's RAP-219 bipolar mania results; TriGemX's proposed SPAC combination to fund migraine development; Veradermics' second Phase 3 hair-loss study; UroGen's UGN-103 filing acceptance; Nouscom's financing for cancer interception; Ambrose's AM-Pharma acquisition; and ICER's new-drug launch-price and prescription-access findings. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | GSK's Jemperli Wins Accelerated Approval & Disc's Bitopertin Meets Phase 3 Endpoints | 20 Oct 2026 | 00:12:21 | |
FDA granted accelerated approval to GSK's Jemperli (dostarlimab) for biomarker-defined locally advanced rectal cancer, with continued surveillance required for responders. Disc Medicine's bitopertin met both Phase 3 APOLLO co-primary endpoints in erythropoietic protoporphyria after an earlier FDA rejection. The roundup covers Roche and Hansoh's oncology ADC deal, Merck KGaA's acquisition agreement for Silence Therapeutics in polycythemia vera, Lilly's Omvoh (mirikizumab) and Gilead's emvistegrast in ulcerative colitis. Also: AbbVie's ABBV-466 Crohn's data and EyePoint's DURAVYU Phase 3 miss in wet AMD and restructuring. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| AAO 2026 Debrief: Retina's Durability Race & A Stargardt Pill Heads to an FDA Decision | 19 Oct 2026 | 00:13:15 | |
The Pharma Closeout's AAO 2026 Debrief covers the readouts from the American Academy of Ophthalmology meeting in New Orleans that matter for drug, device and payer strategy. Kodiak's DAYBREAK and Ocular Therapeutix's SOL-1 show retina's durability race: fewer injections than fixed-schedule aflibercept, with Eylea HD and Vabysmo untested and the old standard going biosimilar. Belite Bio's tinlarebant heads to a February FDA decision in Stargardt disease, Beacon's VISTA data back a gene therapy filing, and Nanoscope's optogenetic therapy holds at four years. Plus geographic atrophy's next bets, two GLP-1 eye studies pointing in opposite directions, Lytenava's billing-code gap, and what to watch: the October 30 myopia advisory committee and the February 12 Stargardt decision. 0:00 Cold open and introduction 1:06 Story of the Congress: retina's durability race (Kodiak, Ocular, EyePoint) 4:29 The old standard goes biosimilar 5:08 Inherited retinal disease moves into the FDA queue: Belite, Beacon, Nanoscope 8:00 Geographic atrophy: PRIMA, K8 and OCU410 9:45 GLP-1 drugs and the eye: two studies, two directions 11:01 Roundup: Lytenava's billing code, Oculis, SpyGlass 12:14 What to watch: the myopia advisory committee and the Stargardt decision Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Week in Review | Revita Slows Regain After Tirzepatide at Six Months; Liquidia Settles With United Therapeutics | 19 Oct 2026 | 00:45:35 | |
Fractyl Health reports that its investigational Revita met the six-month co-primary endpoint of the double-blind, sham-controlled REMAIN-1 pivotal study in adults who lost weight on tirzepatide and then stopped it; the twelve-month co-primary is expected in early 2027. Liquidia and United Therapeutics settled all pending patent litigation: Yutrepia stays available for PAH, Liquidia has asked FDA to remove PH-ILD from the label, and total obligations come to $380.7 million. Alex Mercer and Maya Patel cover Revita's safety and missing-data context, then turn to Verdiva's terminated switch-maintenance study, Biomea's BMF-650 Phase 1 data with its confined-placebo caveat, CHMP opinions for Lilly's oral Foundayo and for broadening Tryngolza in severe hypertriglyceridemia, Roche's ALK7 RNAi license from Rona, Zealand's AI-designed protein deal with Generate, and OMass Therapeutics' Series C. Also covered: Alaunos' completed Velaris acquisition and separate private placement; BMS's split admilparant Phase 3 and Syndax's IPF exit; Verastem's KRAS G12D pancreatic cohort and planned first-line Phase 3; CHMP opinions for Rasonque and Talvey; BNT113, Anktiva's papillary-only expansion and Nurix; tab-cel's accepted FDA resubmission; CHMP's confirmed negative opinion on re-examination for Omeros's narsoplimab; KB113 and RYZ101; Modus's sevuparin enrollment pause, Estuary's launch and Novartis's terminated iptacopan lupus nephritis study; maralixibat, obexelimab and garetosmab data; the Zilbrysq autoinjector, ARO-MAPT and Vanda's VQW-765 result and program hold; Anaphylm's FDA review date; FDA approvals for Enspryng in thyroid eye disease and RYZUMVI in presbyopia; interim six-year MIUDELLA data; Galderma's agreement to buy ZO Skin Health; Osivax's flu vaccine result; Pfizer's Enodia deal; IPOs from Iambic and City Therapeutics; China's export-control registration and draft catalog; a CMS proposed rule with PBM provisions; FDA's rare-disease framework initiative; and Marengo's upcoming ESMO presentation. The episode closes on the week's shared CHMP meeting and its different outcomes, the still-open question of weight maintenance after obesity drugs stop, and financings at different stages of completion. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com. | |||
| Daily Roundup | Enspryng Approved for Thyroid Eye Disease as Home Injection & Omeros Refused Again by EU Panel | 17 Oct 2026 | 00:11:57 | |
Friday, October 16 edition. Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for narsoplimab and plans to end compassionate use there. Alex Mercer and Maya Patel unpack the patient, evidence and commercial implications. Also covered: Talvey’s proposed earlier-line use in Europe; Arrowhead’s early ARO-MAPT tau data in healthy volunteers; Foundayo’s European committee recommendations; RYZUMVI’s presbyopia approval; China’s draft drug-technology export controls; and Labcorp’s agreement to acquire select BioReference assets. Recorded for Friday, October 16; released October 17 after a freshness check. | |||
| Daily Roundup | Anktiva Expands Bladder Cancer Label & Vanda's Anxiety Trial Misses | 16 Oct 2026 | 00:13:31 | |
FDA expanded ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its Phase 3 social-anxiety trial missed, while Vir and Gilead agreed a solid-tumor T-cell engager collaboration. The roundup covers a European recommendation for Revolution Medicines' daraxonrasib in pancreatic cancer, Osivax's OVX836 influenza-vaccine miss, and Alvotech/Advanz's AVT29 high-dose Eylea (aflibercept) biosimilar filing. Galderma's planned ZO Skin Health acquisition and OrbiMed's $3 billion in fund commitments round out the day. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | BioNTech's Cancer Trial Setback & Roche's Fat-Cell Bet | 15 Oct 2026 | 00:13:16 | |
October 14, 2026 edition, released October 15, 2026. BioNTech's BNT113 missed progression-free survival in its pivotal head and neck cancer trial, leaving overall survival as the remaining path to a positive result. Roche licensed Rona Therapeutics' undisclosed ALK7-targeting RNAi obesity candidate—a fat-cell approach with most potential deal value contingent on milestones. Johnson & Johnson raised full-year guidance as newer medicines offset Stelara erosion; the roundup also covers FDA review of FYB206, a proposed Keytruda (pembrolizumab) biosimilar, Syndax ending axatilimab in IPF, 84-week Pasatru (garetosmab) data in FOP, and Tremfya (guselkumab) analyses in Crohn's perianal fistulas. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Bristol's Split IPF Result & RYZ101's Phase 3 Win | 13 Oct 2026 | 00:12:37 | |
Monday, October 12, 2026 edition, released Tuesday, October 13, 2026. News checked through October 13, 2026; no material updates to the stories below were found. Bristol's admilparant met its Phase 3 lung-function endpoint at the lower dose, while the higher dose missed significance in idiopathic pulmonary fibrosis. Its acquired RYZ101 program also delivered a Phase 3 win in neuroendocrine tumors after lutetium therapy, with benefit size still undisclosed. Mirum's LIVMARLI (maralixibat) reduced childhood itch in EXPAND, while the roundup covers First Tracks' ANB033 in celiac disease, Sebela's tegoprazan in reflux, Zenas' obexelimab in IgG4-related disease, Claris' eye-drop data and Ascelia's Orviglance regulatory path. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Week in Review | AstraZeneca's $2B Summit Bet, Merck's Eye Trial & Roche's Vamikibart Filing | 12 Oct 2026 | 00:44:17 | |
Merck's remigromig met BRUNELLO's noninferiority bar in diabetic macular edema, but showed no superiority and a notable safety imbalance. AstraZeneca completed its $2 billion Summit Therapeutics investment around ivonescimab combinations, while Roche's vamikibart entered FDA review with mixed Phase 3 evidence behind the filing. The Sunday, October 11 Week in Review—released Monday, October 12—also spans oncology, cardiometabolic and rare disease, respiratory and neuroscience, immunology, vaccines, infectious disease, access and medicine safety. Across 45 news stories and three forward watches, Alex and Maya separate completed events and clinical results from filings, plans and pending catalysts. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| MDS 2026 Debrief: Two Genetic Bets Fall in Full Data & Juvmo Meets Its Payers | 12 Oct 2026 | 00:16:02 | |
The Pharma Closeout's MDS 2026 Debrief covers the readouts from the International Parkinson and Movement Disorder Society congress in Seoul that matter for drug, diagnostic and payer strategy. Biogen and Denali'sLUMA and Bial's ACTIVATE showed full data on two genetic bets in Parkinson's disease that missed, and we look at what still stands: Arvinas's LRRK2 degrader, a spinal-fluid marker that could help pick patients, and Roche's prasinezumab Phase 3. AbbVie's newly approved Juvmo meets ICER's numbers, and we put Cerevance's solengepras result against the approved add-ons. Plus Syntara's trial in REM sleep behaviour disorder, a skin test for alpha-synuclein, Praxis's essential tremor drug, Teva's ecopipam in Tourettesyndrome, Neurocrine's five-year valbenazine data, and what to watch: the Huntington's congress, ICER's final report, Austedo's Medicare price and Praxis's FDA date. 0:00 Cold open and introduction Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Hovilpri Wins FDA Approval & Biohaven Licenses BHV-1300 to Ono for $80M at Closing | 10 Oct 2026 | 00:07:59 | |
Friday, October 9 edition, released late Saturday, October 10. FDA approved Hovilpri (pritelivir) for immunocompromised adults with stubborn herpes simplex lesions, but the oral drug is not yet available and is expected in the U.S. before the end of 2026. Biohaven agreed to license rights for parts of Asia to Phase 3 Graves' disease candidate BHV-1300 to Ono for $80 million at closing, plus a separate conditional $20 million; the deal is not evidence of efficacy. Also: J&J reports two-year Icotyde PASI 90 results without a long-term Sotyktu comparison, and Pennsylvania details GSK's $800 million-plus Upper Merion manufacturing expansion. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Tecentriq Approved After dMMR Colon Cancer Surgery & Zenbexus Topline: Median PFS 42 vs 20 Months | 09 Oct 2026 | 00:10:12 | |
Thursday, October 8 edition, published after midnight Pacific. FDA approves Roche's Tecentriq (atezolizumab) with chemotherapy after stage III dMMR colon cancer surgery: fewer recurrence-or-death events, more frequent grade 3–4 adverse events. Bristol Myers Squibb reports a topline median progression-free survival of 42 vs 20 months for Zenbexus (iberdomide) in multiple myeloma; the result is not peer-reviewed, reports no overall survival result, and whether it verifies clinical benefit is the FDA's call. argenx stops its Phase 3 UNITY study of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) in Sjögren's disease and says FB102 met its Phase 2 celiac primary endpoint. Plus Viatris's pending $1.65 billion Pacira deal (EXPAREL, ZILRETTA), PhRMA's GLOBE lawsuit, GenSight's GS030 retinitis pigmentosa study and Valneva's UK IXCHIQ revocation. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Pfizer Adds a Breast Cancer Maintenance Choice & MimiVax's Brain Cancer Vaccine Misses | 08 Oct 2026 | 00:07:38 | |
Pfizer's Tukysa (tucatinib) wins a breast cancer maintenance approval after delaying progression, while MimiVax's SurVaxM misses its overall glioblastoma survival goal despite a younger-patient signal. Halozyme reports an injunction against subcutaneous Keytruda (pembrolizumab) in eight European markets; Caribou said yesterday it plans to halt its two donor CAR-T programs amid financing pressure. Cerevance's investigational solengepras cuts Parkinson's off time by 37 minutes a day beyond placebo. Novartis reports FDA approval of Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | ArriVent’s Lung Cancer Pill Hits Setback & Alector’s $100M Genentech Deal | 07 Oct 2026 | 00:08:09 | |
ArriVent's firmonertinib missed its Phase 3 primary progression-free-survival endpoint in lung cancer, with its next step still undecided; this delayed Tuesday edition was recorded October 6. Alector grants Genentech worldwide rights to preclinical Parkinson's program AL050 for $100 million committed upfront and up to $1.17 billion in milestones, with brain delivery untested in people. FDA seeks public input on early ibogaine trials—not an approval—and ViiV reports investigational Cabenuva (cabotegravir/rilpivirine) results in people with detectable HIV, without rates, confidence intervals or detailed safety. Forbion raises €2.3 billion in fund commitments, with first investments already made. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com. | |||
| EASD 2026 Debrief: Type 2 Diabetes Care Moves Earlier & Foundayo Meets a Heart-Safety Bar | 06 Oct 2026 | 00:17:26 | |
The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight orobesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived from Novo on stepping up semaglutide versus switching, from Abbott on continuous glucose monitors, and from a Nordic study on semaglutide and pancreatic cancer. Plus the journal papers on retatrutide, survodutide and petrelintide, type 1 diabetes screening in children across Europe, and what to watch: Lilly and Novo results and ObesityWeek. 0:00 Cold open and introduction Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Genmab's Epkinly Wins Frontline Trial & Vaxcyte's Vaccine Passes With Caveats | 06 Oct 2026 | 00:08:20 | |
Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare neurology, and CSL–Alentis for kidney-disease antibody lixudebart. CMS finalized rules for future prescription-drug files that could improve market-access pricing visibility if the schedule holds. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Week in Review | Lilly's Retatrutide Dose Data, Novartis' RNA Deal & Jaypirca's Approval | 05 Oct 2026 | 00:46:51 | |
Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for Abogen's autoimmune RNA program, and Sanofi-Regeneron expands its long-acting antibody partnership. Ovarian-cancer datasets, Mirum's hepatitis D results and uniQure's Huntington's filing show why patient populations and control groups matter. CMS rebates and medicine tariffs reach manufacturer economics, alongside retina, respiratory and rare-disease updates. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| ASTRO 2026 Debrief: Who Still Needs Hormone Therapy & Protons vs Photons in Liver Cancer | 04 Oct 2026 | 00:25:57 | |
The Pharma Closeout's ASTRO 2026 Debrief covers the readouts from the American Society for Radiation Oncology meeting that matter for drug,diagnostic and payer strategy. Fourteen-year RTOG 0815 data re-open how much hormone therapy men need with prostate radiation, as Veracyte's Decipher andArtera compete to decide who can skip it. The NRG-GI003 plenary showed no survival improvement for protons over photons in liver cancer, Novocure's TRIDENT timing trial missed, and new data arrived on PSMA imaging, radioligands, SBRT versus surgery and lung immunotherapy after SABR. Plus what to watch: theLantheus shareholder vote on the Curium takeover. 0:00 Introduction1:17 Story of the Congress: who still needs hormone therapy with radiation Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at thepharmacloseout.com. | |||
| Daily Roundup | Jaypirca Adds a First-Line CLL Choice & Novartis Signs $575M Abogen License | 03 Oct 2026 | 00:08:47 | |
Delayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a trial against older chemotherapy guide today's treatment choice? Novartis agrees to $575 million upfront for Abogen's early-stage RNA medicine ABO2203, with closing still pending and autoimmune benefit unproven. Also: Pfizer's Litfulo (ritlecitinib) advances toward vitiligo filings; Biogen reports longer-term litifilimab results in cutaneous lupus without a continuing placebo comparison; and Bayer plans a $2.2 billion Ohio manufacturing site. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Survodutide Phase 3 Comes With GI Tolerability Cost & Trevogrumab Trims Lean-Tissue Loss on Scans | 02 Oct 2026 | 00:08:35 | |
Boehringer's survodutide reached up to 13.1% weight loss in Phase 3 assuming patients stayed on treatment, but GI-related dropouts complicate its place in obesity and Type 2 diabetes. CMS's final GLOBE rule tests international prices in Medicare Part B rebates: what changes for patients and doctors? Regeneron's trevogrumab reduced lean-mass loss on scans with semaglutide, without proving greater strength. Also: Sanofi and Regeneron expand their Dupixent alliance with four long-acting antibodies; Foghorn and Lilly stop FHD-909 expansion after insufficient efficacy; and Wave's WVE-006 gets a potential registration path in alpha-1 antitrypsin deficiency. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Lilly's amylin add-on brings more weight loss and more dropouts & Rafael plans NDA after NPC miss | 01 Oct 2026 | 00:11:34 | |
September 30 edition, released October 1. Date references in the audio are anchored to September 30. Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weight loss vs 14.8% for tirzepatide in a secondary Phase 2b comparison, while more patients stopped over adverse events. Rafael Holdings' Trappsol Cyclo missed its Phase 3 TRANSPORT-NPC goal in Niemann-Pick disease type C, yet a fourth-quarter filing is still planned. The daily roundup covers Roche's fenebrutinib Priority Review in MS, Merck's tulisokibart in hidradenitis suppurativa, Pierre Fabre's Ebvallo (tabelecleucel) resubmission and NorthStar's actinium-225 financing. Plus Connect Biopharma's rademikibart in COPD flares, with its safety caveats. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | uniQure's Mixed Huntington's Readout & AstraZeneca's $2B Summit Deal | 30 Sep 2026 | 00:14:21 | |
September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongside a cancer-combination program, without acquiring Summit's drug rights. In the roundup: Veracyte's retrospective Decipher analysis in prostate cancer; FDA approval of Teva's Xgeva biosimilar; and Novo's license to Hengrui's early oral GLP-1/GIP program. Invivyd reports tolerability, not protection, results for VYD2311, and we examine the September 29 implementation of Section 232 drug tariffs. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup| Mirum's Brelovitug Wins Phase 3 on Two Schedules & Kodiak's Zenkuda: 54% Reach Six-Month Dosing | 29 Sep 2026 | 00:15:47 | |
Mirum's brelovitug met Phase 3 AZURE-1's virus-plus-ALT endpoint on weekly and every-four-week dosing in chronic hepatitis delta; durable liver outcomes were not shown. Kodiak's Zenkuda and tabirafusp were noninferior to aflibercept 2 mg on vision in wet AMD, and 54% of Zenkuda patients reached a 24-week interval; neither was compared with newer alternatives. 4DMT started Phase 3 testing of 4D-150 in diabetic macular edema, while Roche will return emugrobart rights to Chugai after an obesity trial's interim efficacy stop. Also: Egetis won FDA approval for Emcitate (tiratricol) for peripheral thyrotoxicosis in MCT8 deficiency, Adicet reported early prula-cel lupus data, Merck licensed preclinical SPR2015, and BARDA backed SCYNEXIS's SCY-247. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Full Week in Review | Gilead's Anito-cel, Genentech's Gazyva & Myeloma's New Cure Standard | 28 Sep 2026 | 00:48:32 | |
This full Week in Review is a comprehensive review of the week's covered stories across oncology, kidney and immune disease, respiratory disease, metabolic disease, neuroscience, rare disease and ophthalmology, plus financings, deals and five events ahead. Gilead's anito-cel gets its full peer-reviewed Phase 1 record before a December FDA target; myeloma groups define cure; and Genentech's Gazyva wins approval to reduce relapse risk in childhood-onset nephrotic syndrome. Also in the review: Lilly's once-weekly Onswik approval, Otsuka and Ionis's Phase 3 ulefnersen result in FUS-ALS, Beacon's pivotal laru-zova win, and regulatory, safety and evidence updates across the covered therapeutic areas, followed by the week ahead. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup | Mirum Wins FOP Approval Despite Primary Endpoint Miss & Carvykti's Five-Year Data | 26 Sep 2026 | 00:12:08 | |
Mirum's Atebrioz (zilurgisertib) wins FDA approval for FOP despite a primary-endpoint miss; Carvykti (ciltacabtagene autoleucel) shows five-year disease control without maintenance in half of 20 myeloma patients. aTyr plans another efzofitimod trial in sarcoidosis. The roundup covers Pharming's Joenja (leniolisib), ADARx's IPO, Canada's Epkinly (epcoritamab) expansion, Novo–Nanexa's long-acting peptide deal, FDA nominee Heidi Overton's hearing, and Medicaid's GENEROUS pricing plan. September 25 edition, published September 26: relative dates and pending events reflect the original reporting cutoff. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup| Merck–Eisai Win Kidney Cancer Approval & Lilly Joins Weekly Insulin Race | 25 Sep 2026 | 00:11:12 | |
Welireg plus Lenvima gains FDA approval in advanced clear-cell kidney cancer, with better disease control but no demonstrated survival advantage. Lilly says FDA approved weekly insulin Onswik, entering a market where Novo’s Awiqli is already available. Merck’s remigromig meets its pivotal vision goal, but safety and dosing questions remain. Plus: Acadia advances after a Phase 2 miss; Kyverna reports autoimmune follow-up; Elevar gains bile-duct cancer approval; Takeda’s Adzynma gets a boxed warning; and Gossamer files despite PROSERA’s miss. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||
| Daily Roundup| GRAIL's Galleri Vote Puts Label and Coverage in Focus & Roche Posts Phase 3 Kidney Win | 24 Sep 2026 | 00:13:11 | |
GRAIL’s Galleri won backing from FDA advisers, but the narrow effectiveness split and a missed late-stage-cancer endpoint keep the label and coverage case in focus. Roche and Ionis report that sefaxersen reduced proteinuria in Phase 3 IgA nephropathy, while longer-term kidney-function data remain blinded and Novartis’s Fabhalta (iptacopan) sets the benchmark. Vertex tests inaxaplin in additional APOL1 kidney disease groups, and Amgen’s dazodalibep succeeds in systemic Sjögren’s disease. Plus: Immunovant halts its cutaneous lupus program, Oruka extends psoriasis follow-up, Boehringer Ingelheim signs an Envisagenics cancer-target pact, and Enveda raises $311 million. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com. | |||